PROGESTA 400 Price

Overview

Welcome to Dwaey, specifically on PROGESTA 400 Vaginal Pessaries page.
This medicine contains an important and useful components, as it consists of Progesterone.
PROGESTA 400 is available in the market in concentration 400mg/Pessery and in the form of Vaginal Pessaries.

JORDAN RIVER PHARMACEUTICAL INDUSTRIES is the producer of PROGESTA 400 and it is imported from JORDAN, The most popular alternatives of PROGESTA 400 are listed downward .

Mode Of Action

Progesterone is the main hormone secreted by corpus luteum. It induces secretory changes in the endometrium, promotes mammary gland development, relaxes uterus, blocks follicular maturation and ovulation, and maintains pregnancy.

Indication

• Premenstrual syndrome
• Contraception
• Menopausal HRT
• Amenorrhoea
• Recurrent miscarriage

Precaution

Family history of breast cancer and or DVT/PE, current/history of depression, endometriosis, DM, HTN, bone mineral density changes, renal/hepatic impairment, bone metabolic disease, SLE; conditions exacerbated by fluid retention (eg, migraine, asthma, epilepsy). Discontinue if the following develop jaundice, visual problems (may cause contact lens intolerance), any signs of VTE, migraine with unusual severity, significang blood pressure increase, severe depression, increased risk of thromboembolic complications after surgery. Discontinue 4 week before major surgery or prolonged immobilization. Patients on warfarin, oral anticoagulants (increase in anticoagulant dose may be warranted). Some studies link OCP use with increased risk of breast cancer, whereas other studies have not shown a change in risk. Increased risk of cervical cancer with OCP use, however HPV remains as main risk factor for this cancer. Evidence suggests long-term use of OCPs, 5 or more years, may be associated with increased risk. Increased risk of liver cancer with OCP use; risk increases with longer duration of OCP use. May cause dizziness; use caution when driving a motor vehicle or operating machinery Increased risk of developing probable dementia in postmenopausal women >65 years of age reported Use with caution in patients with history of depression Use with caution in patients with diseases that could become exacerbated by fluid retention including epilepsy, migraine, renal dysfunction, diabetes, or asthma

Side Effects

• >10% Headache (10-31%)
• Breast tenderness (16-27%)
• Dizziness (15-24%)
• Abdominal pain (10-20%)
• Depression (19%)
• Breast pain (6-16%)
• Viral disease (7-12%) 1-10% Vaginal discharge (10%)
• Fatigue (8-9%)
• Nausea (8%)
• Mood swings (6%) Frequency Not Defined Dementia
• probable(postmenopausal women >65 years of age
• possible association)
• Anorexia
• Weakness
• Weight change (less common than with synthetic progestins)
• Vomiting
• Edema
• DVT (postmenopausal women 50-79 years of age)
• Thrombophlebitis
• Myocardial infarction (postmenopausal women 50-79 years of age)
• Stroke (postmenopausal women 50-79 years of age)
• Pulmonary emboli (postmenopausal women 50-79 years of age)
• Amenorrhea (less common than with synthetic progestins)
• Breakthrough bleeding (less common than with synthetic progestins)
• Change in menstrual flow(less common than with synthetic progestins)
• Spotting (less common than with synthetic progestins)
• Breast changes (less common than with synthetic progestins)
• Invasive breast cancer(postmenopausal women 50-79 years of age)
• Cholestatic jaundice
• Vaginal candidiasis
• General pruritus
• Ectopic pregnancy

Contra indication

Hypersensitivity; thrombophloebitis; cerebral apoplexy; severe hepatic impairment; undiagnosed vag bleeding, incomplete abortion, hormone-dependent carcinoma, as a diagnostic test for pregnancy; pregnancy. History or current high risk of arterial disease.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.